SGK1-mediated deficits in microglial phagocytosis drive pathological progression in amyotrophic lateral sclerosis

Meijun He1, Chaoran Wu1,2, Mengqiu Hu1

  • 1New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China.

Insights

Amyotrophic lateral sclerosis (ALS) involves altered microglial phagocytosis. This study reveals serum- and glucocorticoid-regulated kinase 1 (SGK1) impairs microglial debris clearance in ALS mice, suggesting SGK1 as a therapeutic target.

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Microglial dysfunction is a key feature of amyotrophic lateral sclerosis (ALS).
  • The precise mechanisms regulating microglial phagocytosis during ALS progression are not fully understood.

Purpose of the Study:

  • To investigate the dynamics of microglial phagocytic activity in ALS models.
  • To identify molecular regulators of microglial phagocytosis in ALS.
  • To evaluate SGK1 as a potential therapeutic target for ALS.

Main Methods:

  • Utilized SOD1G93A mouse models of ALS.
  • Performed single-cell RNA sequencing and transcriptomic analysis.
  • Investigated the effects of SGK1 knockout and pharmacological inhibition (GSK650394).

Main Results:

  • Microglial phagocytic activity changed with disease stage in SOD1G93A mice.
  • SGK1 was identified as a key regulator, suppressing microglial clearance of debris and promoting lipid accumulation by inhibiting lipophagy.
  • SGK1 knockout or inhibition improved debris clearance, reduced neuronal engulfment, attenuated motor deficits, and prolonged survival.

Conclusions:

  • SGK1 plays a critical role in impairing microglial phagocytosis in ALS.
  • Targeting SGK1 offers a promising therapeutic strategy for SOD1 mutation-associated ALS.

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...